NO20005290L - Riluzol- og levodopa kombinasjoner for behandling av Parkinsons sykdom - Google Patents

Riluzol- og levodopa kombinasjoner for behandling av Parkinsons sykdom

Info

Publication number
NO20005290L
NO20005290L NO20005290A NO20005290A NO20005290L NO 20005290 L NO20005290 L NO 20005290L NO 20005290 A NO20005290 A NO 20005290A NO 20005290 A NO20005290 A NO 20005290A NO 20005290 L NO20005290 L NO 20005290L
Authority
NO
Norway
Prior art keywords
riluzole
disease
parkinson
treatment
levodopa
Prior art date
Application number
NO20005290A
Other languages
English (en)
Other versions
NO329032B1 (no
NO20005290D0 (no
Inventor
Veronique Blanchard-Bregeon
Assunta Imperato
Saliha Moussaoui
Marie-Carmen Obinu
Michel Reibaud
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of NO20005290D0 publication Critical patent/NO20005290D0/no
Publication of NO20005290L publication Critical patent/NO20005290L/no
Publication of NO329032B1 publication Critical patent/NO329032B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • External Artificial Organs (AREA)
NO20005290A 1998-04-24 2000-10-20 Kombinasjon av riluzol- og levodopa samt anvendelse derav NO329032B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9805153A FR2777781B1 (fr) 1998-04-24 1998-04-24 Associations riluzole et l-dopa pour le traitement de la maladie de parkinson
PCT/FR1999/000953 WO1999055336A1 (fr) 1998-04-24 1999-04-22 Associations de riluzole et de levodopa pour le traitement de la maladie de parkinson

Publications (3)

Publication Number Publication Date
NO20005290D0 NO20005290D0 (no) 2000-10-20
NO20005290L true NO20005290L (no) 2000-10-20
NO329032B1 NO329032B1 (no) 2010-08-02

Family

ID=9525640

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20005290A NO329032B1 (no) 1998-04-24 2000-10-20 Kombinasjon av riluzol- og levodopa samt anvendelse derav

Country Status (22)

Country Link
US (1) US6387936B1 (no)
EP (1) EP1071422B1 (no)
JP (1) JP2002512963A (no)
KR (1) KR100597170B1 (no)
AT (1) ATE386520T1 (no)
AU (1) AU768069B2 (no)
CA (1) CA2329636C (no)
CY (1) CY1110448T1 (no)
CZ (1) CZ300825B6 (no)
DE (1) DE69938179T2 (no)
DK (1) DK1071422T3 (no)
ES (1) ES2300141T3 (no)
FR (1) FR2777781B1 (no)
HU (1) HU228902B1 (no)
IL (1) IL139164A (no)
NO (1) NO329032B1 (no)
PT (1) PT1071422E (no)
RU (1) RU2225204C2 (no)
SK (1) SK285531B6 (no)
UA (1) UA70319C2 (no)
WO (1) WO1999055336A1 (no)
ZA (1) ZA200005758B (no)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2786101B1 (fr) * 1998-11-24 2002-07-05 Aventis Laboratoire Utilisation de la nicergoline dans le traitement de la spasticite
US6872739B1 (en) * 1999-06-04 2005-03-29 Vereniging Voor Christelijk Wetenshappelikjk Onderwijs Use of riluzole for the treatment of multiple sclerosis
GB0007193D0 (en) * 2000-03-25 2000-05-17 Univ Manchester Treatment of movrmrnt disorders
US8158149B2 (en) * 2004-05-12 2012-04-17 Chelsea Therapeutics, Inc. Threo-DOPS controlled release formulation
WO2004100929A1 (en) 2003-05-12 2004-11-25 Synergia Pharma, Inc. Threo-dops controlled release formulation
WO2005025561A1 (en) * 2003-09-04 2005-03-24 Synergia Pharma, Inc. Compositions and methods for orthostatic intolerance
WO2005112906A2 (en) * 2004-05-21 2005-12-01 Duke University Method for augmenting the effects of serotonin reuptake inhibitors
SE0401842D0 (sv) * 2004-07-12 2004-07-12 Dizlin Medical Design Ab Infusion and injection solution of levodopa
WO2006060120A2 (en) * 2004-11-07 2006-06-08 Guilford F Timothy Liposomal formulation for oral administration of glutathione (reduced)
GB0504103D0 (en) * 2005-02-28 2005-04-06 Syngenta Ltd Novel method
US20070148238A1 (en) * 2005-06-23 2007-06-28 Spherics, Inc. Dosage forms for movement disorder treatment
US20080131492A1 (en) * 2006-06-23 2008-06-05 Spherics, Inc. Dosage forms for movement disorder treatment
DK1948155T3 (da) * 2006-06-28 2012-07-02 Chelsea Therapeutics Inc Farmaceutiske præparater omfattende droxidopa
EP2063867A2 (en) * 2006-12-22 2009-06-03 Combinatorx, Incorporated Pharmaceutical compositions for treatment of parkinson's disease and related disorders
US8008285B2 (en) * 2007-03-09 2011-08-30 Chelsea Therapeutics, Inc. Droxidopa and pharmaceutical composition thereof for the treatment of fibromyalgia
AU2008248382B2 (en) * 2007-05-07 2013-07-18 Chelsea Therapeutics, Inc. Droxidopa and pharmaceutical composition thereof for the treatment of mood disorders, sleep disorders, or attention deficit disorders
EP2320892A2 (en) * 2008-06-30 2011-05-18 Novartis AG Combination products
CA2742841A1 (en) * 2008-11-06 2010-05-14 Biotie Therapies, Inc. Treatment of restless leg syndrome and sleep disorders
EP2228054A1 (en) * 2009-03-13 2010-09-15 ITALFARMACO S.p.A. Riluzole aqueous suspensions
ES2703255T3 (es) 2010-10-22 2019-03-07 Univ Duke Formulaciones de liberación lenta de 5-hidroxitriptófano como un complemento para terapias pro-serotoninérgicas
JP5880913B2 (ja) 2011-05-17 2016-03-09 三郎 佐古田 パーキンソン病の体幹症状（姿勢反射異常）の治療剤
US9463186B2 (en) 2013-04-15 2016-10-11 Northwestern University Treatment for dopaminergic disorders

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2700117B1 (fr) * 1993-01-07 1995-02-03 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement de la maladie de Parkinson et des syndromes parkinsoniens.
RU2057529C1 (ru) * 1994-05-30 1996-04-10 Алексей Михайлович Коршунов Способ лечения синдрома паркинсонизма

Also Published As

Publication number Publication date
AU768069B2 (en) 2003-12-04
IL139164A0 (en) 2001-11-25
NO329032B1 (no) 2010-08-02
FR2777781B1 (fr) 2004-04-09
CA2329636C (fr) 2009-09-08
JP2002512963A (ja) 2002-05-08
ES2300141T3 (es) 2008-06-01
RU2225204C2 (ru) 2004-03-10
FR2777781A1 (fr) 1999-10-29
NO20005290D0 (no) 2000-10-20
DE69938179T2 (de) 2009-02-12
EP1071422A1 (fr) 2001-01-31
IL139164A (en) 2005-12-18
SK15882000A3 (sk) 2001-04-09
AU3425599A (en) 1999-11-16
WO1999055336A1 (fr) 1999-11-04
CY1110448T1 (el) 2015-04-29
DE69938179D1 (de) 2008-04-03
DK1071422T3 (da) 2008-06-16
ATE386520T1 (de) 2008-03-15
HUP0101645A3 (en) 2002-10-28
US6387936B1 (en) 2002-05-14
CA2329636A1 (fr) 1999-11-04
EP1071422B1 (fr) 2008-02-20
ZA200005758B (en) 2002-01-17
SK285531B6 (sk) 2007-03-01
CZ300825B6 (cs) 2009-08-19
KR100597170B1 (ko) 2006-07-05
UA70319C2 (en) 2004-10-15
HU228902B1 (en) 2013-06-28
CZ20003908A3 (cs) 2001-02-14
PT1071422E (pt) 2008-05-05
HUP0101645A2 (hu) 2001-09-28
KR20010042960A (ko) 2001-05-25

Similar Documents

Publication Publication Date Title
NO20005290L (no) Riluzol- og levodopa kombinasjoner for behandling av Parkinsons sykdom
GB0108592D0 (en) Therapeutic agents
CY2018020I2 (el) Θεραπεια της νοσου ρομρε
ATE346039T1 (de) Sulfonamido-substituierte verbrückte bicycloalkylderivative
PL310475A1 (en) Application of anticonvulsants in treating neuro-aids diseases
SI1303272T1 (sl) Derivati benzotiazola za zdravljenje alzheimerjeve bolezni in parkinsonove bolezni
FI20000720L (fi) Pitkitettyyn vapautumiseen perustuva tablettiformulaatio Parkisonin taudin hoitamiseksi
YU401A (sh) Sredstva sa antidepresivnim dejstvom
NO20001869L (no) FremgangsmÕte for behandling av Alzheimers sykdom
DE69832695D1 (de) Verwendung von r-enantiomeren nichtsteroidaler entzündungshemmer zur vorbeugung der alzheimerschen krankheit
ES2177024T3 (es) Empleo de la fanquinoma para el tratamiento de la enfermedaad de alzheimer.
HUP9904029A3 (en) Use of 2-(3,4-dimethoxycinnamoyl)aminobenzoic acid for the manufacture of a medicament for the treatment or prevention of restenosis
EA200000816A1 (ru) Применение 2-амино-6-трифторметоксибензотиазола для профилактики или лечения дисфункции мозжечка
DK1133297T3 (da) Ny terapeutisk anvendelse af 1,6-dimethyl-8beta-hydroxymethyl-10alpha-methoxyergolin
AU2003287513A8 (en) Inhibitors of beta-secretase, and their use for the prevention or treatment of alzheimer's disease or mild cognitive impairment
ATE323486T1 (de) Verwendung des riluzols oder dessen salzen zur phophylaxe und behandlung der adrenoleukodystrophie
NO970190D0 (no) Preparat til behandling av Parkinsons sykdom

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees